CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

brexucabtagene autoleucel

Last Updated: November 20, 2020
Result type: Reports
Project Number: PG0219-000
Product Line: Reimbursement Review

Generic Name: brexucabtagene autoleucel

Brand Name: TBC

Manufacturer: Gilead Sciences Canada Inc.

Therapeutic Area: Mantle cell lymphoma

Indications: For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi).

Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi).

Submission Type: Initial

Tumour Type: Lymphoma

Project Status: Pending

Call for patient/clinician input open: November 20, 2020

Call for patient/clinician input closed: January 22, 2021

Anticipated Date: December 18, 2020

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback